ClinicalTrials.gg
Active, not recruitingNCT05306340Updated Nov 3, 2026

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

A Phase 3 interventional study of Giredestrant and Exemestane in Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, sponsored by Genentech, Inc.. Active, not recruiting at 136 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026Study completion moved12 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
373
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing giredestrant in Breast Neoplasms — 4 open to participants now, 12 under way, 7 of them phase 3. giredestrant · Breast Neoplasms.

Enrollment
7th of 16
373 · median 302
Started
2022
with 1 other
Phase 3
7 of 16
2 open now
Primary completion
2025-07
later than 1 of 11 live
Registered
7th of 16
by date
Lead sponsor
4 of 16
Genentech, Inc.

Among the 16 studies testing giredestrant in Breast Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2022, is one of 7 in phase 3, reaches primary completion later than 1 of the 11 other live ones, and was the 7th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 16 studies testing giredestrant in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About giredestrant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing giredestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.

03

Conditions studied

  • Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Locally advanced unresectable or adenocarcinoma of the breast, not amenable to treatment with curative intent
  2. Documented estrogen receptor-positive (ER+) tumor and -negative tumor, assessed locally
  3. Ability to provide a blood sample for circulating-tumor deoxyribonucleic acid (ctDNA) Estrogen Receptor 1 (ESR1) mutation status determination by central testing
  4. Prior endocrine therapy (ET) in combination with cyclin-dependent kinase 4/6 inhibitors in either setting as follows:

    • Metastatic setting: Disease progression after ≥6 months on ET plus CDK4/6 inhibitor in the locally advanced or metastatic setting. If ET plus CDK4/6 inhibitor is not the most recent therapy, then patient must also have had disease progression after ≥4 months on most recent ET
    • Setting: Relapse either while taking or within 12 months of exposure to combination adjuvant ET and CDK4/6 inhibitor. Patients must have taken at least 12 months of adjuvant ET, 6 months of which was in combination with a CDK4/6 inhibitor.
  5. as defined per v.1.1 or evaluable bone metastases. Patients with evaluable bone disease in the absence of measurable disease outside of the bone must have at least one predominantly lytic bone lesion confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) which can be followed
  6. Performance Status 0-1
  7. For women who are premenopausal or perimenopausal and for men: treatment with approved luteinizing hormone-releasing hormone (LHRH) agonist therapy for the duration of study treatment

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with another oral selective estrogen receptor degrader (SERD), proteolysis targeting chimera (PROTAC), complete estrogen receptor antagonist (CERAN), novel oral selective estrogen receptor modulator (SERM), or everolimus in any setting. Prior fulvestrant is allowed if treatment was terminated at least 28 days prior to randomization. Prior treatment with tamoxifen is allowed.
  2. Progression on more than 2 prior lines of systemic endocrine therapy in the locally advanced unresectable or breast cancer setting
  3. Prior chemotherapy for locally advanced unresectable or metastatic disease
  4. Treatment with strong Cytochrome P450 3A4 () inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization
  5. Treatment with any therapy within 28 days prior to initiation of study treatment
  6. Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 14 days prior to randomization
  7. History of any other other than breast cancer within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, papillary thyroid cancer treated with surgery, Stage I endometrial cancer, or other non-breast cancers at very low risk of recurrence
  8. Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
  9. Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or
  10. Active cardiac disease or history of cardiac dysfunction
  11. Known history of liver disease consistent with Class B or C including active viral or other hepatitis virus, current alcohol abuse, or cirrhosis
  12. Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major upper gastrointestinal (GI) surgery including gastric resection
  13. Interstitial lung disease or severe dyspnea at rest or requiring oxygen therapy
  14. Serious infection requiring oral or intravenous (IV) antibiotics, or other clinically significant infection, within 14 days prior to randomization
  15. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
  16. Known allergy or to any of the study drugs or any of their
  17. For premenopausal or perimenopausal women and for men: known hypersensitivity to LHRH agonists
  18. Pregnant or breastfeeding
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
373 participants (actual)

Study arms

  • Experimental
    Giredestrant plus Everolimus

    Drug: Giredestrant · Drug: Everolimus · Drug: LHRH Agonist · Drug: Dexamethasone Mouth Rinse

  • Active comparator
    Physician's Choice of Endocrine Therapy plus Everolimus

    The physician's choice of endocrine therapy is defined as either exemestane, fulvestrant, or tamoxifen.

    Drug: Exemestane · Drug: Fulvestrant · Drug: Tamoxifen · Drug: Everolimus · Drug: LHRH Agonist · Drug: Dexamethasone Mouth Rinse

Interventions

  • Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).

    Also known as: GDC-9545, RO7197597, RG6171

  • If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.

  • If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.

  • If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.

  • Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

  • Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

  • A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population

    The Intent-to-Treat (ITT) population consists of all randomized participants, and the ESR1m subpopulation is defined as participants in the ITT population whose tumors harbor a detectable Estrogen Receptor 1 (ESR1) mutation at baseline as measured in circulating tumor DNA (ctDNA).

    Time frame: From randomization until the first occurrence of disease progression or death from any cause, whichever occurs first (up to 42 months)

Secondary outcomes

  1. Overall Survival, in the ESR1m Subpopulation and ITT Population

    Time frame: From randomization until death from any cause (up to 42 months)

  2. Objective Response Rate (ORR), as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population

    The objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions at least 4 weeks apart.

    Time frame: From randomization until progressive disease or death (up to 42 months)

  3. Duration of Response (DOR), as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population

    Time frame: From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 42 months)

  4. Clinical Benefit Rate (CBR), as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population

    The clinical benefit rate is defined as the percentage of participants with stable disease for at least (≥)24 weeks or a complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart.

    Time frame: From Baseline until progressive disease or death (up to 42 months)

  5. Time to Confirmed Deterioration in Pain Severity, as Determined Using the Brief Pain Inventory Short-Form (BPI-SF) Worst Pain Item Score, in the ESR1m Subpopulation and ITT Population

    Time to confirmed deterioration in pain severity is defined as the time from randomization to the first documentation of ≥2-point increase from baseline on the "worst pain" item score (scale from 0 = "No pain" to 10 = "Pain as bad as you can imagine") held for 2 consecutive time points, or a ≥2-point increase followed by death attributable to cancer progression within 28 days from the last assessment.

    Time frame: From randomization until 90 days after treatment discontinuation (up to 42 months)

  6. Time to Confirmed Deterioration in Pain Presence and Interference, as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed Pain Scale Score, in the ESR1m Subpopulation and ITT Population

    Time to confirmed deterioration in pain presence and interference is defined as the time from randomization to the first documentation of ≥10-point increase in pain score held for 2 consecutive time points, or a ≥10-point increase followed by death attributable to cancer progression within 28 days from the last assessment. EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life-Core 30

    Time frame: From randomization until 90 days after treatment discontinuation (up to 42 months)

  7. Time to Confirmed Deterioration in Physical Functioning (PF), as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed PF Scale Score, in the ESR1m Subpopulation and ITT Population

    Time to confirmed deterioration in physical functioning (PF) is defined as the time from randomization to the first documentation of ≥10-point decrease in PF score held for 2 consecutive time points, or a ≥10-point decrease followed by death attributable to cancer progression within 28 days from the last assessment. EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life-Core 30

    Time frame: From randomization until 90 days after treatment discontinuation (up to 42 months)

  8. Time to Confirmed Deterioration in Role Functioning (RF), as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed RF Scale Score, in the ESR1m Subpopulation and ITT Population

    Time to confirmed deterioration in role functioning (RF) is defined as the time from randomization to the first documentation of ≥10-point decrease in RF score held for 2 consecutive time points, or a ≥10-point decrease followed by death attributable to cancer progression within 28 days from the last assessment. EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life-Core 30

    Time frame: From randomization until 90 days after treatment discontinuation (up to 42 months)

  9. Time to Confirmed Deterioration in Health-Related Quality of Life (HRQoL), as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed Global Health Status (GHS)/QoL Scale Score, in the ESR1m Subpopulation and ITT Population

    Time to confirmed deterioration in HRQoL is defined as the time from randomization to the first documentation of ≥10-point decrease in GHS/QoL score held for 2 consecutive time points, or a ≥10-point decrease followed by death attributable to cancer progression within 28 days from the last assessment. EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life-Core 30

    Time frame: From randomization until 90 days after treatment discontinuation (up to 42 months)

  10. Number of Participants with at Least One Adverse Event, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5 (NCI CTCAE v5.0)

    Time frame: From Baseline until 30 days after the final dose of study treatment (up to 42 months)

  11. Number of Participants with Vital Sign Abnormalities Over the Course of the Study

    Vital signs include respiratory rate, pulse rate, systolic and diastolic blood pressure while the patient is in a seated position, and temperature.

    Time frame: From Baseline until 30 days after the final dose of study treatment (up to 42 months)

  12. Number of Participants with Clinical Laboratory Test Abnormalities for Hematology Parameters Over the Course of the Study

    Time frame: From Baseline until 30 days after the final dose of study treatment (up to 42 months)

  13. Number of Participants with Clinical Laboratory Test Abnormalities for Biochemistry Parameters Over the Course of the Study

    Time frame: From Baseline until 30 days after the final dose of study treatment (up to 42 months)

  14. Plasma Concentration of Giredestrant at Specified Timepoints

    Time frame: Predose and 3 hours postdose on Days 1 and 15 of Cycle 1, and predose on Day 1 of Cycles 2 and 3 (1 cycle is 28 days)

07

Study locations

136 sites

Showing the first 100 of 136 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Mayer EL, Tolaney SM, Martin M, Vidal GA, Moscetti L, Jhaveri KL, Brufsky A, Gradishar WJ, Schneeweiss A, Niikura N, Favret A, Alfie M, Lee KS, Khan S, Feldman MB, Day BM, Lam LH, Darbonne WC, Shah MD, Griffiths KL, DiLallo G, Perez-Moreno PD, Rugo HS; evERA Breast Cancer Investigators. Giredestrant plus Everolimus in Advanced Breast Cancer. N Engl J Med. 2026 Oct 1;395(13):1285-1298. doi: 10.1056/NEJMoa2602457. PubMed 42814929 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jul 2025, 35 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 35 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jun 2027, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2022
First posted
Apr 1, 2022
StartActual
Aug 3, 2022
Primary completionActual
Jul 16, 2025
CompletionEst.
Jun 15, 2027was Oct 2026
Results delay requested
Apr 24, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 12 sites removed
Show 12 added (10 Spain, 1 Argentina, 1 United Kingdom)
  • Centro Medico Privado CEMAIC · Córdoba, Argentina
  • Hospital Dexeus · Barcelona, Spain
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • C.H. Regional Reina Sofia - PPDS · Córdoba, Spain
  • Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología · A Coruña, Spain
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
  • Hospital Universitario Ramón y Cajal · Madrid, Spain
  • Hospital Clinico San Carlos · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital General Universitario J.M Morales Meseguer · Murcia, Spain
  • Hospital Clinico Universitario de Valencia · Valencia, Spain
  • The Christie NHS Foundation Trust - SSC Parent · Manchester, United Kingdom
Show 12 removed
  • Centro Medico Privado CEMAIC · Córdoba, Argentina
  • Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología · A Coruña, Spain
  • Hospital Dexeus · Barcelona, Spain
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • C.H. Regional Reina Sofia - PPDS · Córdoba, Spain
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
  • Hospital Universitario Ramón y Cajal · Madrid, Spain
  • Hospital Clinico San Carlos · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital General Universitario J.M Morales Meseguer · Murcia, Spain
  • Hospital Clinico Universitario de Valencia · Valencia, Spain
  • The Christie NHS Foundation Trust - SSC Parent · Manchester, United Kingdom
Nov 3, 2026
Study completion
Oct 15, 2026→Jun 15, 2027
Nov 3, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42814929 ↗
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42814929 ↗
    12 sites added, 12 sites removed
    Show 12 added (10 Spain, 1 Argentina, 1 United Kingdom)
    • Centro Medico Privado CEMAIC · Córdoba, Argentina
    • Hospital Dexeus · Barcelona, Spain
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • C.H. Regional Reina Sofia - PPDS · Córdoba, Spain
    • Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología · A Coruña, Spain
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    • Hospital Universitario Ramón y Cajal · Madrid, Spain
    • Hospital Clinico San Carlos · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital General Universitario J.M Morales Meseguer · Murcia, Spain
    • Hospital Clinico Universitario de Valencia · Valencia, Spain
    • The Christie NHS Foundation Trust - SSC Parent · Manchester, United Kingdom
    Show 12 removed
    • Centro Medico Privado CEMAIC · Córdoba, Argentina
    • Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología · A Coruña, Spain
    • Hospital Dexeus · Barcelona, Spain
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • C.H. Regional Reina Sofia - PPDS · Córdoba, Spain
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    • Hospital Universitario Ramón y Cajal · Madrid, Spain
    • Hospital Clinico San Carlos · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital General Universitario J.M Morales Meseguer · Murcia, Spain
    • Hospital Clinico Universitario de Valencia · Valencia, Spain
    • The Christie NHS Foundation Trust - SSC Parent · Manchester, United Kingdom
    Study completion Oct 15, 2026→Jun 15, 2027
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05306340
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Apr 1, 2022
Start date
Aug 3, 2022
Primary completion
Jul 16, 2025
Completion
Jun 15, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Giredestrant

Start the discussion